Swiss drugmaker Roche will combine two production operations in Basel in a move that will cut up to 190 jobs over this year and next, it said on Thursday.
Merging the active substance and small molecule drug production lines reflects the company’s changing portfolio, focusing more on specialised drugs in smaller volumes, it said in a statement.
Small molecule substances are used in the large majority of most traditional drugs.
The company said lower overall capacity will be required as its older drugs, which require significantly higher production volumes, lose patent protection.
Roche employs about 15,000 staff in Switzerland.
By Paul Arnold
Source: Reuters
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
